PBFT02
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72
Trial Timeline
Sep 14, 2021 → Aug 1, 2031
NCT ID
NCT04747431About PBFT02
PBFT02 is a phase 1/2 stage product being developed by Passage Bio for Frontotemporal Dementia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04747431. Target conditions include Frontotemporal Dementia, FTD, FTD-GRN.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04747431 | Phase 1/2 | Recruiting |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 41 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 52 |
| memantine hydrochloride | Lundbeck | Phase 3 | 74 |
| Syntocinon | Brain Biotech | Phase 2 | 44 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 36 |